Abstract: Oxime-substituted compounds are preferably cyclic or heterocyclic compounds. The oxime-substituted compounds and pharmaceutical compositions thereof have the formula:CORE MOIETY--(R).sub.jincluding resolved enantiomers (both syn and anti forms) and/or diastereomers, hydrates, salts, solvates and mixtures thereof. j is an integer from one to three, the core moiety is non-cyclic or cyclic and R may be selected from among: hydrogen, halogen, hydroxyl, amino, substituted or unsubstituted C.sub.(1-10), alkyl, C.sub.(2-10) alkenyl, cyclic or heterocyclic groups, and formula I. At least one R has the formula I:--(CH.sub.2).sub.n --C--(R.sub.1).sub.p, Iwherein n is an integer from three to twenty; p is two or three; R.sub.1 is selected from among hydrogen; halogen; hydroxide; substituted or unsubstituted C.sub.(1-10) alkyl, C.sub.(1-10) alkoxy, C.sub.(2-10) alkenyl, cyclic or heterocyclic group; =N--OR.sub.2, R.sub.2 being hydrogen or a substitute or unsubstituted C.sub.(1-10) alkyl, C.sub.
Abstract: The invention relates generally to a method of increasing creatine supply depot of mammals having no disorders in the creatine metabolism, viz. Healthy, thereby increasing muscular strength, shortening the period of re-establishment of phosphorous compounds in energy after work and increasing the body of the muscles. This is achieved by the administration of creatine to the mammals in an amount of at least 15 grams, or 0.2-0.4 g/kg body weight or preferably about 0.3 g/kg body weight, per day for at least 2 days. The invention describes the use of creatine for the manufacturing of a preparation to increase the muscle performance ability in an amount which supplies a daily dose as stated above and a method.
Abstract: The epidermal permeability barrier to systemically and/or topically active agents or compositions designed for topical administration is enhanced to an unexpected degree by certain combinations of known penetration enhancing excipients. One group of combinations comprise a glycol and an alcohol at a weight ratio within the range of 1:0.1 to 1:10 with one or more further additives, selected from the excipient groups of branched-chain esters of fatty acids, surfactants, and membrane fluidizers. Another group of combinations comprise an alcohol of four or more carbon atoms and one or more further additives selected from the excipient groups of glycols and surfactants.
Abstract: The present invention relates to methods for treating cocaine and amphetamine dependency. The method involves administering to the patient an effective amount of a compound having the formula: ##STR1## wherein R.sup.1 is selected from the group consisting of hydrogen and C1 to C6 alkyl;R.sup.2 is selected from the group consisting of hydrogen, methyl, and ethyl;R.sup.3 is selected from the group consisting of hydrogen, methyl, C1 to C6 alkanoyl, C3 to C6 cycloalkanoyl, and pyridinecarbonyl;Q is a bivalent alkylene moiety; andY is selected from the group consisting of a halo-(C2 to C6)-alkenyl moiety having 1 or 2 chlorine or bromine atoms attached to the ethylenic carbon, a cycloalkyl moiety, a cyano moiety, and a cyano-(C3 to C6)-alkenyl moietyor a pharmaceutically acceptable acid-addition salt thereof. Discomforting side effects can be minimized by optionally administering naltrexone, naloxone, or a mixture thereof during the early phases of treatment.
Abstract: Methods of controlling phosphate metabolism and metabolic acidosis in patients suffering from renal failure and associated hyperphosphatemia or patients predisposed to development of a hyperphosphatemic condition are provided. The method in accordance with this invention comprises administering to a patient a ferric-containing compound selected from the group consisting of ferric citrate, ferric acetate, and combinations thereof. Therapeutic benefit can be realized in accordance with such method by administering the compound orally to a patient to contact and bind with ingested phosphate in the patient's digestive tract, and thereby prevent its intestinal absorption.
Abstract: The use of colloidal silica for the treatment of sickle-cell anaemia, malaria and exogenously induced leucopenias leads to a significant improvement in the condition of the patients.
Type:
Grant
Filed:
September 21, 1995
Date of Patent:
May 19, 1998
Inventors:
Alfred Schmidt, Emmanuel Bisse, Heinrich Wieland
Abstract: The present invention provides methods and products for inhibiting neutrophil adhesion and neutrophil aggregation. The invention includes a method for treating a subject to inhibit neutrophil adhesion and neutrophil aggregation by administering 16-hydroxyeicosatetraenoic acid (16-HETE) to the subject. 16-HETE is an arachidonic acid metabolite. The invention also includes a pharmaceutical preparation of 16-HETE.
Type:
Grant
Filed:
May 22, 1996
Date of Patent:
May 19, 1998
Assignee:
University of Vermont
Inventors:
Martin M. Bednar, Cordell E. Gross, Michael Balazy, John R. Falck
Abstract: The antireactive-antiasthmatic effect of inhaled loop diuretics is potentiated by the use of a combination of a loop diuretic and a non-steroidal anti-inflammatory drug as an inhalant for combating asthma. The use of a cyclooxygenase inhibitor as the non-steroidal anti-inflammatory drug is preferred, particularly preferred is the use of furosemide as the loop diuretic. Especially advantageous is the use of piretanide as the loop diuretic. Particularly preferred is the use of acetylsalicylic acid as the non-steroidal anti-inflammatory drug.The most remarkable finding of this invention is the excellent and steady protective effect afforded by the combination of the two drugs in the patients with late asthmatic reactions between the seventh and eighth hour, when the effect of treatment with either drug alone appeared to be progressively decreasing.
Abstract: The invention provides oxygenated solutions, such as beverages, useful for the alleviation of halitosis. Further provided are methods of using these solutions in remediating mouth odor.
Abstract: Dental compositions comprise an abrasive, a humectant material, water and a binder. The abrasive comprises sodium aluminosilicate product having a water demand of greater than 50 g water per 100 g product, and the dental compositions comprise a water to abrasive weight ratio greater than 1.
Abstract: Angiogenesis is a composite of regulated proliferation and regulated invasion occuring in a variety of normal and pathologic conditions. Compound 1 and related analogs are useful for inhibiting angiogenesis in a host and offer a novel approach to the treatment of cancer, diabetic retinopathy, hemangiomata, vasculidities and other diseases associated with angiogenesis.
Type:
Grant
Filed:
March 10, 1994
Date of Patent:
April 28, 1998
Assignee:
United States of America
Inventors:
Elise C. Kohn, Lance A. Liotta, Riccardo Alessandro
Abstract: A method is disclosed for preparing ammonium hydroxyalkyl sulfonate by a process of reacting ammonium bisulfite and alkylene oxide wherein the pH is maintained at a relatively low value throughout most of the time of reaction of ammonium bisulfite and alkylene oxide in order to minimize the quantity of impurities, e.g. alkylene glycol and alkanolamine, in the ammonium hydroxyalkyl sulfonate. Ammonium alkanoyl alkyl sulfonates prepared by reacting such ammonium hydroxyalkyl sulfonates with fatty acids form aqueous solutions which are clear at ambient temperatures, and thus are useful as surfactants in clear liquid products.
Type:
Grant
Filed:
July 28, 1995
Date of Patent:
April 14, 1998
Assignee:
PPG Industries, Inc.
Inventors:
Robert G. Briody, Amy E. Doty, Cheruthur Govindan, Louis J. Nehmsmann, Alan E. Wang
Abstract: A pharmaceutical formulation of taxol and polyethoxylated castor oil is disclosed to be relatively acidified to a pH of less than 8.1 and preferably within a pH range of 5 to 7, inclusively, by an acidifying agent. Ethanol is optionally included in the formulation which is adapted for use in a body for the treatment of cancer. A formulation method is disclosed and includes the step of mixing an acid with a carrier material, such as polyethoxylated castor oil, to form a carrier solution after which taxol is added in an amount such that the resulting pH is less than 8.1 and preferably in a pH range of 5 to 7. Ethanol may optionally be slurried with the taxol before mixing with the carrier solution. A variety of acidifying agents, a preferred one being anhydrous citric acid, are described.
Type:
Grant
Filed:
January 31, 1996
Date of Patent:
March 31, 1998
Assignee:
NaPro BioTherapeutics, Inc.
Inventors:
David Carver, Timothy Prout, Hernita Ewald, Robyn Elliott, Paul Handreck
Abstract: A method of inhibiting degeneration of neural cells comprising treating the cells with an effective degeneration-inhibiting amount of one or more compounds of Formula I: ##STR1## wherein R is a C.sub.12 to C.sub.22 linear or branched alkyl group, or pharmaceutically-acceptable salts thereof is disclosed.
Abstract: Compounds and a method useful for protection of tissue cells in a mammalian body from irreversible damages due to lactic acidosis caused by oxygen deficiency. The protection is achieved by administering a compound having a cell membrane permeability and/or ability to cross the blood brain barrier, said compound being able to provide a buffering action to prevent an increase in a hydrogen ion concentration over the physiologically acceptable levels or able to shift the intracellular pH to a more desired alkaline level.
Abstract: The present invention is directed to compositions containing angiostatic compounds and methods for their use in preventing pathological neovascularization.
Type:
Grant
Filed:
August 7, 1995
Date of Patent:
February 17, 1998
Assignee:
Alcon Laboratories, Inc.
Inventors:
Rupa Doshi, Jon Nixon, Robert J. Collier, Jr.
Abstract: An improved process for the production of a pharmaceutical composition comprising p-hydroxyacetanilide and L-cysteine or a compound which is converted thereto in vivo comprises mixing p-hydroxyacetanilide and L-cysteine or its precursor in the solid state and then shaping the solid mixture.
Abstract: This invention relates to methods of treating neurological illnesses related to acetylcholine deficiency in the CNS including memory loss attending senility, Parkinson's disease, Down's syndrome or senile pugilistica by administering a therapeutically effective compound of the formula: ##STR1## where R.sub.1, R.sub.2 and R.sub.3 are, independently, H, alkyl, halo, perhaloalkyl, hydroxy, alkoxy, aryl or arylalkyl; n is an integer from 0-5; R is azabicyclo?2.2.2!octyl or azabicyclo?2.2.1!heptyl when n.sub.1 is zero, or R is NR.sub.4 R.sub.5 when n.sub.1 is 1, 2, 3, 4, or 5, in which R.sub.4 and R.sub.5 are alkyl or R.sub.4 and R.sub.5, taken with the nitrogen atom to which they are attached, are N-(substituted aryl)piperazinyl in which said substituent is alkoxy, halo or perhaloalkyl; N-(pyridyl)piperazinyl; N-(pyrimidinyl)piperazinyl; or 3-azabicyclo-?3.2.2!non-3-yl; X is oxygen or NH; n and n.sub.1 are, independently, one of the integers 0, 1, 2, 3, 4 or 5; or a pharmaceutically acceptable salt thereof.